REGISTERED NUMBER: 04858627 (England and Wales)

Abbreviated Unaudited Accounts for the Year Ended 31 August 2015

for

Molecular Therapies Ltd

Molecular Therapies Ltd (Registered number: 04858627)

Contents of the Abbreviated Accounts for the Year Ended 31 August 2015

	Page
Company Information	1
Abbreviated Balance Sheet	2
Notes to the Abbreviated Accounts	3

Molecular Therapies Ltd

Company Information for the Year Ended 31 August 2015

DIRECTOR: Mrs H Ahmad

REGISTERED OFFICE: 6 Wayborne Grove

Ruislip England Middlesex HA4 7DU

REGISTERED NUMBER: 04858627 (England and Wales)

ACCOUNTANTS: MEEM Associates

Chartered Certified Accountants

76 Bolton Road Harrow

Middlesex HA1 4SA

Molecular Therapies Ltd (Registered number: 04858627)

Abbreviated Balance Sheet

31 August 2015

	Notes	31.8.15 £	31.8.14 £
CURRENT ASSETS		~	
Debtors		-	12
Cash at bank		130	<u>-</u>
		130	12
CREDITORS			
Amounts falling due within one year		9,831	4,577
NET CURRENT LIABILITIES		<u>(9,701</u>)	(4,565)
TOTAL ASSETS LESS CURRENT			
LIABILITIES		<u>(9,701</u>)	<u>(4,565</u>)
CAPITAL AND RESERVES			
Called up share capital	2	2	2
Retained earnings		_(9,703)	(4,567)
SHAREHOLDERS' FUNDS		<u>(9,701</u>)	<u>(4,565</u>)

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 August 2015.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 August 2015 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges her responsibilities for:

- (a) ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
 - preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 304 and 305 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial
- (b) 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The abbreviated accounts have been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

The financial statements were approved by the director on 27 May 2016 and were signed by:

Mrs H Ahmad - Director

Molecular Therapies Ltd (Registered number: 04858627)

Notes to the Abbreviated Accounts for the Year Ended 31 August 2015

1. ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Financial reporting standard 102 - reduced disclosure exemptions

The company has taken advantage of the following disclosure exemption in preparing these financial statements, as permitted by FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland":

• the requirements of Section 7 Statement of Cash Flows.

Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

2. CALLED UP SHARE CAPITAL

Allotted, issu	ed and fully paid:			
Number:	Class:	Nominal	31.8.15	31.8.14
		value:	£	£
2	Ordinary	1	2	2

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.